Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p.... |
Good MorningStocks ended the day driven by big tech and bank headlines. NVIDIA’s CES showcase and RTX 60-Series debut helped the chip giant briefly push market value above $4.76 trillion before cooling back toward $4.5–$4.6 trillion, keeping AI enthusiasm at the market’s center. JPMorgan reported a 9% adjusted profit rise in Q4—$13.03 billion, or $4.63 a share—though results were trimmed by a one-time 60-cent charge tied to its Apple Card acquisition and $2.2 billion added to loan-loss reserves. December inflation was mostly unchanged while core prices cooled slightly, a development markets watch closely for Fed policy signals.
Policy risk and regulation crept into market thinking. Nine central bankers voiced full solidarity with Fed Chair Powell amid President Trump’s escalating confrontations with the Fed, and Wall Street executives warned that attacks on regulators and the credit card industry could unsettle markets. Microsoft’s Brad Smith pressed lawmakers for Big Tech to shoulder the costs of sprawling AI data centers, signaling potential regulatory and cost pressures for cloud and chip providers. Featured: Elon’s big $266,000 per second purchase (Ad) 
| Markets | |
Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p... Read the Full Story |
| From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
| Medical | |
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%. Optimism surrounding Lilly’s current and developmental weight loss and diabetes t... Read the Full Story |
| Finance | |
A convergence of factors has JPMorgan Chase & Company (NYSE: JPM) stock poised to rally in 2026. The stock surged in 2025 and could advance as much as 20% by year’s end. Below, we'll examine what's driving the JPM market and why the financial stock could see the $400 level this year.
Ja... Read the Full Story |
| From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
| Retail/Wholesale | |
Shares of tech giant Amazon.com Inc (NASDAQ: AMZN) surged more than 10% last week, starting what looks like what could be a decisive run toward November's all-time high. The move hasn't come out of the blue. For months now, the stock has been carving out a steady series of higher lows, quietly b... Read the Full Story |
| Technology | |
In the middle of January 2026, the two largest forces in mobile computing effectively called a truce in the war for artificial intelligence (AI) dominance. After months of speculation and market volatility, Apple Inc. (NASDAQ: AAPL) and Alphabet Inc. (NASDAQ: GOOG) formalized a strategic partnersh... Read the Full Story |
| From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
| Technology | |
The market reaction in the finance and fintech sectors on Jan. 12, 2026, was not a panic sell-off. It was a precise, calculated sorting event. Following the Trump administration's announcement of a proposed 10% cap on credit card interest rates, the financial sector fractured. While the headlines ... Read the Full Story |
| Technology | |
NVIDIA (NASDAQ: NVDA) has achieved a level of dominance in the stock market that defies historical comparison. The chip giant's market capitalization briefly peaked above $4.76 trillion following its dominant presentation at CES 2026, which featured the debut of its new consumer-focused RTX 60-Ser... Read the Full Story |
| Auto/Tires/Trucks | |
After gaining just 6% last year, consumer discretionary stocks entered 2026 looking for some relief from the fallout from tariffs, margin compression, and a weakening labor market.
But for automotive stocks, the situation was a little different. According to Autoweek, U.S. auto sales were strong... Read the Full Story |
| Markets | |
In the face of inflation, changing interest rates, and broader market instability, income-generating exchange-traded funds (ETFs) may be a strong defensive choice for investors in 2026. These funds offer the benefit of steady distributions by focusing on dividend-paying stocks, on bonds, or on oth... Read the Full Story |
| Technology | |
AI is a fast-growing market whose outlook has yet to be fully reflected in its stock prices. While it's hard to say for certain which AI infrastructure, model builder, or application will stand the test of time, it is certain that AI and the cloud are here to stay.
Many organizations use multiple... Read the Full Story |
| Wednesday's Early Bird Stock Of The Day Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. | Should I Buy Pfizer Stock? PFE Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Pfizer was last updated on Monday, July 13, 2026 at 6:21 PM.
Pfizer Bull Case -
Pfizer Inc. recently reported earnings per share (EPS) of $0.75, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
-
The company achieved a revenue of $14.45 billion for the quarter, surpassing estimates, showcasing its ability to generate significant income and maintain a competitive edge in the biopharmaceutical market.
-
Pfizer Inc. has set a fiscal year 2026 guidance of 2.800-3.000 EPS, suggesting confidence in its future earnings potential and growth trajectory.
-
The current stock price is around $28.56, which reflects a reasonable valuation given the company's strong fundamentals and growth prospects.
-
With a dividend yield of 7.1% and a recent quarterly dividend announcement, Pfizer Inc. offers attractive income potential for investors seeking regular returns.
Pfizer Bear Case -
The company's net margin of 11.83% indicates that while it is profitable, there may be concerns about cost management and overall profitability compared to industry peers.
-
Pfizer Inc.'s payout ratio is 131.30%, which suggests that the company is paying out more in dividends than it is earning, raising concerns about the sustainability of its dividend payments.
-
Analysts have mixed ratings on the stock, with a significant number assigning a "Hold" rating, indicating uncertainty about its future performance.
-
Revenue growth of 5.4% year-over-year, while positive, may not be sufficient to meet the high expectations set by investors and analysts, potentially leading to volatility in stock performance.
-
Recent downgrades from some brokerages, including a reduction in price targets, may signal a lack of confidence in the stock's short-term performance.
| | View Today's Stock Pick |
|
| |
|
|
